APA

French P. J., Eoli M., Sepulveda J. M., de Heer I., Kros J. M., Walenkamp A., Frenel J., Franceschi E., Clement P. M., Weller M., Ansell P., Looman J., Bain E., Morfouace M., Gorlia T. & van den Bent M. (20200806). Defining EGFR amplification status for clinical trial inclusion. : Neuro-oncology.

Chicago

French Pim J, Eoli Marica, Sepulveda Juan Manuel, de Heer Iris, Kros Johan M, Walenkamp Annemiek, Frenel Jean-Sebastien, Franceschi Enrico, Clement Paul M, Weller Michael, Ansell Peter, Looman Jim, Bain Earle, Morfouace Marie, Gorlia Thierry and van den Bent Martin. 20200806. Defining EGFR amplification status for clinical trial inclusion. : Neuro-oncology.

Harvard

French P. J., Eoli M., Sepulveda J. M., de Heer I., Kros J. M., Walenkamp A., Frenel J., Franceschi E., Clement P. M., Weller M., Ansell P., Looman J., Bain E., Morfouace M., Gorlia T. and van den Bent M. (20200806). Defining EGFR amplification status for clinical trial inclusion. : Neuro-oncology.

MLA

French Pim J, Eoli Marica, Sepulveda Juan Manuel, de Heer Iris, Kros Johan M, Walenkamp Annemiek, Frenel Jean-Sebastien, Franceschi Enrico, Clement Paul M, Weller Michael, Ansell Peter, Looman Jim, Bain Earle, Morfouace Marie, Gorlia Thierry and van den Bent Martin. Defining EGFR amplification status for clinical trial inclusion. : Neuro-oncology. 20200806.